Market cap of Ironwood Pharmaceuticals Inc [IRWD] reaches 1.49B – now what?

- Advertisements -

Ironwood Pharmaceuticals Inc [NASDAQ: IRWD] gained 3.14% on the last trading session, reaching $9.52 price per share at the time. The company report on November 9, 2023 at 7:00 AM that Ironwood Pharmaceuticals Reports Third Quarter 2023 Results.

– LINZESS® (Iinaclotide) EUTRx prescription demand growth increased 8% year-over-year; LINZESS U.S. net sales of $279 million, an increase of 7% year-over-year –.

– Reported positive final data from STARS Nutrition, a Phase II study of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) and colon-in-continuity (CIC) –.

Ironwood Pharmaceuticals Inc represents 154.03 million in outstanding shares, while the company has a total market value of $1.49 billion with the latest information. IRWD stock price has been found in the range of $8.89 to $9.915.

- Advertisements -

If compared to the average trading volume of 2.61M shares, IRWD reached a trading volume of 3423961 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Ironwood Pharmaceuticals Inc [IRWD]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IRWD shares is $17.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IRWD stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Jefferies have made an estimate for Ironwood Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on Nov-10-23.

- Advertisements -

The Average True Range (ATR) for Ironwood Pharmaceuticals Inc is set at 0.40, with the Price to Sales ratio for IRWD stock in the period of the last 12 months amounting to 3.48. Price to Free Cash Flow for IRWD in the course of the last twelve months was 5.64 with Quick ratio for the last quarter at 1.04.

Trading performance analysis for IRWD stock

Ironwood Pharmaceuticals Inc [IRWD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.90. With this latest performance, IRWD shares gained by 0.85% in over the last four-week period, additionally sinking by -7.21% over the last 6 months – not to mention a drop of -18.70% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IRWD stock in for the last two-week period is set at 54.62, with the RSI for the last a single of trading hit 57.56, and the three-weeks RSI is set at 52.71 for Ironwood Pharmaceuticals Inc [IRWD]. The present Moving Average for the last 50 days of trading for this stock 9.18, while it was recorded at 9.38 for the last single week of trading, and 10.31 for the last 200 days.

Ironwood Pharmaceuticals Inc [IRWD]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Ironwood Pharmaceuticals Inc [IRWD] shares currently have an operating margin of +60.97 and a Gross Margin at +99.65. Ironwood Pharmaceuticals Inc’s Net Margin is presently recorded at +42.64.

Return on Total Capital for IRWD is now 23.29, given the latest momentum, and Return on Invested Capital for the company is 17.27. Return on Equity for this stock inclined to 27.83, with Return on Assets sitting at 15.72. When it comes to the capital structure of this company, Ironwood Pharmaceuticals Inc [IRWD] has a Total Debt to Total Equity ratio set at 63.75. Additionally, IRWD Total Debt to Total Capital is recorded at 38.93, with Total Debt to Total Assets ending up at 37.79. Long-Term Debt to Equity for the company is recorded at 63.28, with the Long-Term Debt to Total Capital now at 38.65.

Reflecting on the efficiency of the workforce at the company, Ironwood Pharmaceuticals Inc [IRWD] managed to generate an average of $799,384 per employee. Receivables Turnover for the company is 3.58 with a Total Asset Turnover recorded at a value of 0.37.Ironwood Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.04 and a Current Ratio set at 1.04.

An analysis of Institutional ownership at Ironwood Pharmaceuticals Inc [IRWD]

The top three institutional holders of IRWD stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in IRWD stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in IRWD stock with ownership which is approximately 5.7994%.

- Advertisements -

Leave a Reply

Your email address will not be published. Required fields are marked *